Company: SHPH
Filing Date: 2025-03-05
Form Type: S-1/A
Source: 0001493152-25-009106
Chunk: 53

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-05
Form: S-1/A
Chunk 53
---
   |     |          |         40,245,587 |   |
| Accumulated deficit                                                                                                  |     |        |             (34,578,101 | ) |     |           |             (34,066,584 | ) |     |          |        (34,066,584 | ) |
| Total stockholders’ equity                                                                                           |     |        |                 709,152 |   |     |           |                 709,152 |   |     |          |          6,179,152 |   |
| Total capitalization                                                                                                 |     | $      |               1,585,412 |   |     |           |               1,585,412 |   |     | $        |          7,055,412 |   |

The number of shares of common stock issued and outstanding actual, pro forma and pro forma as adjusted in the table above excludes 1,231,910 shares reserved for issuance under our 2018 Equity Incentive Plan; 3,464,281 warrants which remain subject to exercise; and 1,826,000 pre-existing unexercised pre-funded warrants.

<div align='center'>DILUTION</div>

If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the public offering price per share of our common stock and the as adjusted net tangible book value per share of our common stock immediately after this offering. As of December 31, 2024, our historical net tangible book value was $709,152, or $.12 per share. Our historical net tangible book value is the amount of our total tangible assets less our total liabilities. Historical net tangible book value per share represents historical net tangible book value divided by 5,902,567 shares (4,076,567 shares of our common stock outstanding and another 1,826,000 shares of common stock issuable under pre-existing pre-funded warrants) as of December 31, 2024.

After giving effect to the acceleration of restricted stock units and our issuance and sale of common stock, or Pre-Funded Warrants on lieu thereof, in this offering at an assumed public offering price of $.60 per share, which is the last reported trading price of our common stock on the Nasdaq on February 26, 2025, and after deducting estimated underwriting fees and estimated transaction expenses payable by us, our pro forma as adjusted net tangible book value as of December